Strategic Collaboration Between Sandoz Group AG and Shanghai Henlius Biotech Inc.
Sandoz Group AG announced on 17 August 2026 a landmark collaboration with Shanghai Henlius Biotech Inc. (Henlius) that will substantially broaden its biosimilar portfolio. The agreement, described by the Swiss‑based company as one of the largest in the biosimilar domain, covers up to ten biosimilar assets, of which a bundle of three products has already been agreed.
Scope and Structure of the Agreement
- Commercial Rights – Sandoz will obtain global commercialisation rights outside China.
- Development and Manufacturing – Henlius will retain responsibility for the development, manufacturing, and supply of the assets.
- Milestone‑Based Payments – The total potential consideration is estimated at approximately USD 322 million, with near‑term payments linked to the initial assets.
The arrangement is milestone‑driven, ensuring that payment obligations are contingent on the achievement of predefined development, regulatory, and commercial milestones.
Key Assets Under Collaboration
- Cetuximab Biosimilar – Currently in clinical development for the treatment of epidermal growth factor receptor (EGFR)‑positive cancers.
- Evolocumab Biosimilar – Planned for hypercholesterolaemia and cardiovascular risk reduction; a key candidate given the proven efficacy of the originator in lowering low‑density lipoprotein cholesterol.
- Belimumab Biosimilar – Targeted for systemic lupus erythematosus; the originator has demonstrated significant benefit in reducing disease activity.
- Recombinant Human Hyaluronidase Option – Designed to facilitate subcutaneous administration of biosimilars, potentially improving patient convenience and adherence.
These assets represent a strategic expansion of Sandoz’s portfolio, which is projected to grow from 39 to 46 biosimilar candidates.
Regulatory Pathways and Safety Considerations
- Regulatory Strategy – The collaboration will employ the established biosimilar regulatory frameworks in the United States (FDA) and the European Union (EMA), leveraging Sandoz’s experience in navigating these pathways.
- Safety Data – Pre‑clinical and early clinical safety data for the cetuximab and belimumab biosimilars align with the safety profiles of the respective originators. Ongoing pharmacovigilance will be integrated into post‑marketing commitments.
- Efficacy Outcomes – Interim efficacy data for the evolocumab biosimilar in phase II trials demonstrate LDL‑cholesterol lowering comparable to the reference product, with a similar adverse event profile.
The inclusion of a recombinant hyaluronidase to enable subcutaneous delivery may reduce infusion‑related adverse events and enhance patient satisfaction.
Implications for Patient Care and Healthcare Systems
- Increased Access – By expanding the biosimilar pipeline, the partnership aims to improve patient access to high‑quality biologic therapies across more than 100 countries, especially in regions where cost constraints limit the use of originator biologics.
- Cost‑Effectiveness – Biosimilars typically offer a lower cost of care without compromising clinical outcomes, supporting healthcare systems’ sustainability goals.
- Clinical Practice – The availability of subcutaneous formulations and a broader range of indications may shift prescribing patterns, enabling earlier and more convenient therapeutic interventions.
Strategic Context
The collaboration follows a prior partnership formed in April 2025 that focused on an oncology biosimilar. By adding three additional assets and an option for hyaluronidase, Sandoz reinforces its leadership in the rapidly expanding biosimilar market as patents on original biologics continue to expire.
Conclusion
The Sandoz–Henlius partnership represents a significant strategic step toward expanding the global biosimilar portfolio, enhancing safety and efficacy through rigorous regulatory pathways, and improving access to biologic therapies for patients worldwide. The milestone‑based structure ensures that commercial and clinical objectives remain aligned, while the projected pipeline growth positions Sandoz as a key driver of innovation in the biosimilar space.
